Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70047 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Satoshi Miyamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Thymus Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Lenvatinib is recommended for the treatment of advanced and recurrent thymic carcinomas. However, there is a paucity of data on lenvatinib's use in real‐world clinical practice. The aim of this study was to evaluate the efficacy and safety of lenvatinib in patients with thymic carcinoma.
Methods
This multicenter retrospective cohort study assessed the efficacy and tolerability of lenvatinib in the treatment of patients with advanced or recurrent thymic carcinoma between March 2021 and March 2024.
Results
Twenty‐seven patients from six institutions in Japan were enrolled in this study. The median progression‐free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were 9.0 months (95% confidence interval [CI] 4.8–14.5), 33% (95% CI 16.5%–54%), and 85% (95% CI 66.3%–95.8%), respectively. Although the number of patients was small, the median PFS of the first‐, second‐, and third‐ or later‐line treatment groups was 21.3 months ( n = 5), 9.0 months ( n = 13), and 5.8 months ( n = 9) ( p = 0.171), respectively. Dose reduction was required in all patients, with 17 (63%) presenting grade ≥ 3 adverse events, including hypertension in seven patients and proteinuria in six. No grade ≥ 4 adverse events were observed.
Conclusion
The real‐world efficacy and safety of lenvatinib are consistent with those reported in previous clinical trials of second‐line lenvatinib. Furthermore, despite the relatively small sample size, our findings suggest that lenvatinib may be effective for the treatment of thymic carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.
- Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Department of Internal Medicine, NHO Kinki-Chuo Chest Medical Center, Osaka, Japan.
- Department of Internal Medicine, Saito Yukoukai Hospital, Ibaraki, Osaka, Japan.
- Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Satoshi Miyamoto
Zitieren
APA
Miyamoto, S., Tsukaguchi, A., Kuhara, H., Otsuki, T., Shiroyama, T., Tamiya, M., Tamiya, A., Nishino, K., Takeda, Y., Kijima, T., Okumura, M., Kumanogoh, A., & Mori, M. (2025). Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70047
Vancouver
Miyamoto S, Tsukaguchi A, Kuhara H, Otsuki T, Shiroyama T, Tamiya M, et al. Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70047
BibTeX
@article{Miyamoto2025,
author = {Miyamoto, Satoshi and Tsukaguchi, Akihiro and Kuhara, Hanako and Otsuki, Taiichiro and Shiroyama, Takayuki and Tamiya, Motohiro and Tamiya, Akihiro and Nishino, Kazumi and Takeda, Yoshito and Kijima, Takashi and Okumura, Meinoshin and Kumanogoh, Atsushi and Mori, Masahide},
title = {Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70047}
}
EUVIMED